Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Prelude Therapeutics Inc (NASDAQ: PRLD) closed the day trading at $1.35 down -2.88% from the previous closing price of $1.39. In other words, the price has decreased by -$2.88 from its previous closing price. On the day, 1.14 million shares were traded. PRLD stock price reached its highest trading level at $1.5 during the session, while it also had its lowest trading level at $1.34.
Ratios:
For a better understanding of PRLD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.68 and its Current Ratio is at 3.68. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.20.
On June 20, 2024, Barclays Downgraded its rating to Underweight which previously was Equal Weight but kept the price unchanged to $3.
On March 13, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $7.JMP Securities initiated its Mkt Outperform rating on March 13, 2024, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’25 when Combs Andrew bought 100,000 shares for $0.69 per share. The transaction valued at 69,250 led to the insider holds 480,123 shares of the business.
Vaddi Krishna bought 675,000 shares of PRLD for $467,438 on Mar 25 ’25. The CEO now owns 1,999,296 shares after completing the transaction at $0.69 per share. On Mar 21 ’25, another insider, Vaddi Krishna, who serves as the CEO of the company, bought 15,000 shares for $0.73 each. As a result, the insider paid 10,959 and bolstered with 1,324,296 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRLD now has a Market Capitalization of 76410464 and an Enterprise Value of 47479920. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.92 while its Price-to-Book (P/B) ratio in mrq is 1.01. Its current Enterprise Value per Revenue stands at 6.783 whereas that against EBITDA is -0.356.
Stock Price History:
The Beta on a monthly basis for PRLD is 1.08, which has changed by 0.16806722 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, PRLD has reached a high of $4.22, while it has fallen to a 52-week low of $0.61. The 50-Day Moving Average of the stock is -2.41%, while the 200-Day Moving Average is calculated to be 34.48%.
Shares Statistics:
Over the past 3-months, PRLD traded about 1.22M shares per day on average, while over the past 10 days, PRLD traded about 6532190 shares per day. A total of 43.74M shares are outstanding, with a floating share count of 24.45M. Insiders hold about 56.80% of the company’s shares, while institutions hold 28.73% stake in the company. Shares short for PRLD as of 1760486400 were 515090 with a Short Ratio of 0.42, compared to 1757894400 on 538367. Therefore, it implies a Short% of Shares Outstanding of 515090 and a Short% of Float of 6.8500000000000005.
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.12 and low estimates of -$0.33.
Analysts are recommending an EPS of between -$1.07 and -$1.51 for the fiscal current year, implying an average EPS of -$1.35. EPS for the following year is -$0.9, with 3.0 analysts recommending between -$0.34 and -$1.24.
